Effect of a three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor on erectile dysfunction

Jian Wang*, Peng Wu*, Qiang Liu, Liangliang Ben, Geng Chen, Zhijuan Han and Hui Peng

Abstract
Objective: To investigate the therapeutic effect of implanting a three-piece inflatable penile prosthesis (IPP) combined with the phosphodiesterase-5 inhibitor sildenafil in severe erectile dysfunction (ED) patients.

Methods: This randomized controlled study included 123 ED patients. Sixty-two patients received the IPP implantation and 61 patients received the IPP implantation and the phosphodiesterase-5 inhibitor sildenafil. Erectile function and sexual life quality were evaluated using the five-item International Index of Erectile Function (IIEF) and modified Sexual Life Quality Questionnaire–Quality of Life domain (mSLQQ-QoL), respectively. Serum interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α, vascular cell adhesion molecule (VCAM)-1, and intercellular adhesion molecule (ICAM)-1 levels were assessed. Kaplan–Meier curves were used to assess the overall IPP survival.

Results: Implantation of the three-piece IPP with sildenafil improved erectile function and sexual life quality, alleviated the inflammatory response, reduced the complication rate, and improved overall IPP survival.

Conclusion: Implantation of the three-piece IPP combined with a phosphodiesterase-5 inhibitor significantly improved clinical outcomes and the prognosis in ED patients.

*These authors contributed equally to the work.

Corresponding author:
Hui Peng, Department of Urology, the Second People’s Hospital of Nantong City, 298 Xinhua Road, Gangzha District, Nantong City, Jiangsu Province 226001, China.
Email: jianwang845@126-web.net
Keywords
Three-piece inflatable penile prosthesis, phosphodiesterase-5 inhibitor, erectile dysfunction, sildenafil, erectile function, sexual life quality, Five-item International Index of Erectile Function (IIEF), modified Sexual Life Quality Questionnaire–Quality of Life domain (mSLQQ-QoL)

Date received: 10 June 2020; accepted: 8 December 2020

Introduction

Erectile dysfunction (ED) is defined as a persistent inability to obtain or maintain an erection for satisfying sexual intercourse.1 Worldwide, up to 50% of men aged 40 to 70 years have ED.2 An increasing amount of evidence shows that ED is caused by the interaction of multiple physiologic systems, such as endocrine, neural, and vascular systems.3 Although ED is considered to be an age-related disease, it might have begun to occur in adolescence, especially for those who have risk factors, including cardiovascular diseases, metabolic syndrome, or diabetes.4

Currently, various methods are used to treat ED including seeking assistance from a mental health professional, lifestyle modifications, oral phosphodiesterase type 5 inhibitor (PDE5I), testosterone therapy, intracavernosal injection therapy, a vacuum erection device, and penile prosthesis implantation.5 PDE5Is including avanafil, lodenafil, mirodenafil, and sildenafil have been used clinically as first-line pharmaceuticals to treat ED.6 As previously reported, PDE5Is have a therapeutic effect on ED in patients with spinal cord trauma.7 Additionally, PDE5I administration was shown to be well-tolerated for ED in diabetic men, and it also showed excellent effectiveness.8 The anti-inflammatory effect of PDE5I was also reported in several studies. Kosutova et al.9 revealed that sildenafil treatment suppressed pro-inflammatory mediator release and attenuated oxidative damage in acute lung injury. Therefore, we hypothesized that PDE5I might play an anti-inflammatory role in patients with ED.

Implantation of an inflatable penile prosthesis (IPP) is an effective and safe treatment option for men who do not respond to conventional medical therapy.10 Although IPP implantation was reported to result in better sexual function, and the patients had better feeling as well as higher satisfaction than with other treatment options, it also might result in mechanical failure that requires prosthesis repair, explant, or replacement.11 Moreover, infections commonly result from bacterial implantation on the surface of the device during IPP implantation.12 The three-piece IPP was reported to be a safe and effective approach that has a high satisfaction rate, and its minimally invasive approach could decrease common postoperative complications.13 Therefore, more attention needs to be paid to decreasing the complication rate and alleviating inflammation.

In this study, we performed a randomized controlled trial to investigate the effect implanting a three-piece IPP combined with an PDE5I in patients with severe ED.

Materials and methods

Patients

The present randomized controlled study enrolled 123 patients with severe ED who
were admitted to our hospital from March 2011 to February 2015. All of the patients underwent implantation of a three-piece IPP for the first time. A diagnosis of ED was made on the basis of the patient’s medical history and physical examination and laboratory test results, including the free testosterone and lipid profile. Penile duplex sonography and neurologic examination were used to detect the causes of ED. The diagnostic criteria details were as follows: 1) over 50% failure on sexual intercourse (minimum of four attempts); and 2) a score of less than 11 for the five-item of International Index of Erectile Function (IIEF-5) for more than 6 months. Inclusion criteria were as follows: 1) ED patients with no response to conventional oral pharmacotherapy or intracavernosal injection; 2) ED patients with severe penile curvature, shortening, and impaired penile rigidity; and 3) patients with no intention of maintaining nonsurgical options to treat ED. Patients with a penile curvature greater than 90° were excluded. The present study was approved by the ethics committee at the Second People’s Hospital of Nantong City, and written informed consent was obtained from all of the parents who participated in the study.

Treatments and implantation procedure

All ED patients were randomly divided into the following two groups using a SPSS software (v.18.0, SPSS Inc., Chicago, IL, USA)-generated number list: 1) Control group: IPP implantation; or 2) Observation group: IPP implantation combined with the PDE5I sildenafil at a dose of 50 mg/day for 1 month.

A minimally invasive technique was performed for the implant. First, the patients’ inguinal and penile areas were shaved, and prophylactic antibiotics (1 g vancomycin and 160,000 U gentamicin via intravenous injection) were then administered under general or spinal anesthesia. The three-piece IPP was also immersed in an antibiotic solution (400 mg vancomycin, 800,000 U gentamicin, and 1000 mL 0.9% NaCl). The implantation procedure was conducted under antibiotic cover through a transverse penoscrotal incision. An artificial erection was induced to identify the dorsal nerve and any pathology that required correction, and stay sutures were placed using a lateral placement. After the skin and bilateral corporotomy incisions, the proximal and distal corpora cavernosa were evaluated and dilated. To avoid pump damage from excessive backpressure, the three-piece penile prosthesis was inflated to the maximum distension. The wound was protected by a silver sulphadiazine-impregnated wound dressing (Urgotul-SSD, Urgo Medical, Dijon, France), covered with sterile gauze, and treated with proper pressure. The drainage tube was removed 24 hours after surgery, and the catheter was removed 5 to 7 days later. Additionally, more attention should be paid to preventing urethral injury. Patients with obvious pain were treated with opioid-based analgesia. The prosthesis was activated 8 to 10 days after surgery and patients started using the prosthesis for sexual intercourse 6 weeks later.

Measurement of serum factors

Serum interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α, vascular cell adhesion molecule (VCAM)-1, and intercellular adhesion molecule (ICAM)-1 levels were detected using an enzyme-linked immunosorbent assay (ELISA) at baseline and 5 days after the surgery. Briefly, peripheral venous blood samples were collected from all the ED patients and evaluated using commercial ELISA kits (all purchased from Abcam, Cambridge, MA, USA): human IL-6 ELISA kit (ab46027); human IL-8 ELISA kit (ab214030); human TNF alpha ELISA kit (ab100654); human
VCAM1 ELISA kit (ab223591); and human ICAM1 ELISA kit (CD54) (ab174445).

**Data collection**

Demographic information from all ED patients was recorded, including age, body mass index (BMI), ED cause, ED duration, and intraoperative complications. The IIEF-5 and the modified Sexual Life Quality Questionnaire–Quality of Life domain (mSLQQ-QoL) were used to evaluate erectile function and sexual life quality in patients before treatment and at 2, 3, 6, and 12 months after the surgery. Postoperative complications within 2 weeks were recorded. Follow-up lasted for 5 years from admission to the last follow-up or IPP failure (mechanical or non-mechanical).

**Statistical analysis**

Continuous data are presented as the mean ± standard deviation (SD). Comparisons among three or more groups were performed using a one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test, while comparisons between two groups were made using the Student’s t-test. The chi-square test was used to compare counting materials and rates. Mechanical survival rates of the IPP were assessed using a Kaplan–Meier analysis. P less than 0.05 was considered to be significant. All calculations were performed using SPSS v.18.0 (SPSS Inc.).

**Results**

**Basic characteristics of all erectile dysfunction patients**

One hundred twenty-three patients with severe ED were included in the present randomized controlled study. Patients in both groups received a penile prosthesis implant using the same type of three-piece IPP, but the observation group also received sildenafil at a dose of 50 mg/day for 1 month. There were 62 patients in the IPP group and 61 patients in the IPP and sildenafil group, and their average age was 55.02 ± 7.64 years and 57.74 ± 8.29 years, respectively. During the study period, no patient withdrew or was lost to follow-up. The basic characteristics of all the included patients are shown in Table 1. Patients with IPP implantation and sildenafil had a shorter hospital stay (P < 0.001) and decreased swelling and shorter pain duration (P = 0.036) compared with the control group. No significant difference was found for the other characteristics between the two groups.

*Three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor improved erectile function and sexual life quality*

To investigate the effect of the different therapies on the two study groups, the erectile function and sexual life quality were evaluated using the IIEF-5 scale and the mSLQQ-QoL, respectively. As shown in Figure 1a–b, there was no significant difference in the erectile function score and sexual life quality between the two groups at admission, but the IPP implant combined with a PDE5I significantly increased the IIEF-5 and mSLQQ-QoL scores compared with the IPP implant-only control group (P < 0.001). Moreover, erectile function and sexual life quality scores increased gradually over time at 2 months and 3 months and significant differences were found at these time points (P < 0.001). No difference was found at 6 months and 12 months after the implantation. These findings suggest that the IPP combined with a PDE5I improved erectile function and sexual life quality compared with IPP alone.
Three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor alleviated inflammation

We then determined the serum inflammatory factor levels at admission and 7 days after the treatment. As shown in Table 2, the inflammatory factor levels were increased after surgery in both groups, but there was no difference at admission. IL-6, TNF-α, VCAM-1, and ICAM-1 levels at 5 day were significantly lower in patients with...
IPP implantation and a PDE5I compared with the IPP implantation group ($P < 0.05$). These findings suggest that IPP implantation combined with a PDE5I might decrease inflammatory factor levels compared with IPP alone.

**Three-piece inflatable penile prosthesis combined with a phosphodiesterase-5 inhibitor decreased complications and increased the overall prosthesis survival rate**

We finally analyzed the postoperative complications rate and overall IPP survival rate (mechanical survival and non-mechanical survival) over a 5-year follow-up. As shown in Table 3, the rates of infection and total complications in patients with IPP implantation were significantly higher than those in patients with IPP implantation who were treated with sildenafil ($P < 0.044$ and $P < 0.045$, respectively). There were no differences in the other complications. Moreover, the Kaplan–Meier curve suggested that overall IPP survival was notably lower than the IPP combined with a PDE5I ($P = 0.023$; Figure 2). All the above results revealed that the three-piece IPP combined with a PDE5I decreased

| Table 2. Serum level of pro-inflammatory markers/mediators before and 5 days after treatment. |
|------------------------------------------------------------------------------------------|
|                                                                                           |
| IPP implantation (n = 62)                                                                 |
| IPP implantation combined with phosphodiesterase-5 inhibitor (n = 61)                      |
| Before | After | Before | After | Before | After | Before | After |
| IL-6 (pg/mL) | 103.47 ± 3.60 | 110.37 ± 3.31* | 102.98 ± 3.90 | 105.38 ± 2.97*# |
| IL-8 (pg/mL) | 186.08 ± 8.80 | 211.93 ± 11.48* | 185.16 ± 8.58 | 193.93 ± 8.89*# |
| TNF-α (ng/mL) | 0.66 ± 0.04 | 0.90 ± 0.06* | 0.65 ± 0.35 | 0.72 ± 0.05*# |
| VCAM-1 (ng/mL) | 35.67 ± 3.06 | 54.85 ± 3.33* | 34.57 ± 3.41 | 45.49 ± 3.29*# |
| ICAM-1 (ng/mL) | 1.90 ± 0.06 | 2.22 ± 0.12* | 1.90 ± 0.06 | 2.04 ± 0.09*# |

* $P < 0.05$, comparison of the level of pro-inflammatory markers/mediators at admission and 5 days after the treatment.
# $P < 0.05$, comparison of the level of pro-inflammatory markers/mediators between the IPP implantation group and IPP implantation combined with phosphodiesterase-5 inhibitor group.

IPP, inflatable penile prosthesis; IL, interleukin; TNF-α, tumor necrosis factor; VCAM-1, vascular cell adhesion molecule; ICAM-1, intercellular adhesion molecule.

| Table 3. The incidence of complications after surgery in the two groups after a 5-year follow-up. |
|------------------------------------------------------------------------------------------|
|                                                                                           |
| IPP implantation (n = 62)                                                                 |
| IPP implantation combined with phosphodiesterase-5 inhibitor (n = 61)                      |
| Infections, n (%) | 4 (6.45) | 0 (0) | 0.044 |
| Urethral erosion, n (%) | 2 (3.23) | 0 (0) | 0.157 |
| Prosthesis extrusion, n (%) | 1 (1.61) | 1 (1.64) | 0.311 |
| Mechanical failure, n (%) | 5 (8.06) | 4 (6.56) | 0.784 |
| Scrotal hematoma, n (%) | 1 (1.61) | 0 (0) | 0.319 |
| Overall complication rate, n (%) | 13 (20.97) | 5 (8.20) | 0.045 |

IPP, inflatable penile prosthesis.
complications and increased the overall IPP survival rate compared with IPP alone.

Discussion

A variety of treatments have been successfully used to treat patients with ED, such as vacuum devices, intracavernosal injections, PDE5Is, and penile prosthesis implantation. Although PDE5I use is considered to be a first-line therapy, IPP implantation has gradually become a popular treatment because of its low complication rate and high satisfaction rate.

The three-piece IPP is composed of corporal cylinders, a flow regulator or pump, and a reservoir. The three-piece IPP has been the most frequently used type of penile prosthesis, accounting for over 75% of the currently placed IPPs because of its rigidity, girth expansion, and optimum flaccidity. As reported, the IPP implantation significantly improved the quality of life in ED patients. Another previous study also demonstrated that the three-piece IPP could be safely implanted in ED patients with various urinary diversions, and it had satisfactory outcomes with no increase in the risk of infection or damage to adjacent structures. In this study, we found that the implantation of the three-piece IPP significantly improved the erectile function and sex life quality, which could be further improved using a PDE5I.

The inhibitory effect of sildenafil on the inflammatory response and oxidative stress have been recently illustrated in several studies. Laxmi et al. found that sildenafil served as an inhibitor for inflammation in bronchial asthma in rats. In addition, as stated in a study of severe acute pancreatitis using a rat model, sildenafil administration decreased the level of inflammatory factors (IL-1β, IL-6, and TNF-α). We also, for the first time, observed that a three-piece IPP combined with sildenafil remarkably downregulated IL-6, TNF-α, VCAM-1, and ICAM-1 levels, which means that sildenafil administration might alleviate the inflammatory response in ED. Because IPP implantation is an invasive treatment for ED patients, it might be associated with various complications, such as urinary retention, mechanical failure, and infection. In this study, we also investigated the clinical outcome after implantation. The results showed that IPP implantation combined with sildenafil could increase the overall IPP survival rate and reduce the complication rate, swelling, and pain duration.

The present study also has some limitations. First, the number of ED patients included in this study was limited. Second, we did not enroll a healthy group as a control. Therefore, further study is required.

Conclusion

We conducted a randomized controlled study to investigate the effect of three-piece IPP implantation combined with a PDE5I on erectile function and sexual life quality, inflammation, and the complication rate in severe ED patients.
We showed, for the first time, that implanting a three-piece IPP combined with PDE5I administration might significantly improve the clinical outcomes and patient prognosis.

**Ethics approval and consent to participate**
The present study was approved by the ethics committee at the Second People’s Hospital of Nantong City. Written informed consent was obtained by all participants.

**Consent for publication**
All authors agreed with the submission and the journal’s policies and copyright.

**Availability of data and material**
All of the data in this study can be obtained from the authors upon reasonable request.

**Declaration of conflicting interests**
The authors declare that there is no conflict of interest.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors were supported financially by the project “The research of phosphodiesterase type 5 siRNA carried by adipose stem cells transplanted into the human corpus cavernosum to promote erection” (Jiangsu Health Committee and Nantong Second People’s Hospital, Jiangsu, China; Z2019025).

**ORCID iD**
Jian Wang https://orcid.org/0000-0001-7325-6179

**References**
1. Greenberg DR, Richardson MT, Tijerina JD, et al. The quality of systematic reviews and meta-analyses in erectile dysfunction treatment and management published in the sexual medicine literature. *J Sex Med* 2019; 16: 394–401.
2. Goldstein I, Goren A, Li VW, et al. Epidemiology update of erectile dysfunction in eight countries with high burden. *Sexual Med Rev* 2020; 8(1): 48–58.
3. Rastrelli G, Maggi M. Erectile dysfunction in fit and healthy young men: psychological or pathological? *Translation Androl Urol*, 2017; 6(1): 79.
4. Miner M, Parish SJ, Billups KL, et al. Erectile dysfunction and subclinical cardiovascular disease. *Sex Med Rev* 2019; 7: 455–463.
5. Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. *J Urol* 2018; 200: 633–641.
6. Plácido R and Lainscak M. Phosphodiesterase inhibitors. *International Cardiovascular Forum Journal* 2019; 17: 39–42.
7. García-Perdomo HA, Echeverría-García F and Tobias A. Effectiveness of phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction in patients with spinal cord trauma: systematic review and meta-analysis. *Urol Int* 2016.
8. Liao X, Qiu S, Bao Y, et al. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials. *World J Urol* 2019; 37: 1061–1074.
9. Kosutova P, Mikolka P, Balentova S, et al. Effects of phosphodiesterase 5 inhibitor sildenafil on the respiratory parameters, inflammation and apoptosis in a saline lavage-induced model of acute lung injury. *J Physiol Pharmacol* 2018; 69.
10. Bennett N and Huang IS. Inflatable penile prosthesis in the radical prostatectomy patient: a review. *F1000Res* 2018; 7: 770.
11. Loh-Doyle J, Patil MB, Nakhoda Z, et al. Three-piece inflatable penile prosthesis placement following pelvic radiation: technical considerations and contemporary outcomes. *J Sex Med* 2018; 15: 1049–1054.
12. Gross MS, Phillips EA, Carrasquillo RJ, et al. Multicenter investigation of the micro-organisms involved in penile prosthesis infection: an analysis of the efficacy of the AUA and EAU guidelines for penile
13. Antonini G, Busetto GM, De Berardinis E, et al. Minimally invasive infrapubic inflatable penile prosthesis implant for erectile dysfunction: evaluation of efficacy, satisfaction profile and complications. *Int J Impot Res* 2016; 28: 4–8.

14. Ji YS, Ko YH, Song PH, et al. Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction. *Korean J Urol* 2015; 56: 461–465.

15. Kahraman H, Sen B, Koksal N, et al. Erectile dysfunction and sex hormone changes in chronic obstructive pulmonary disease patients. *Multidiscip Respir Med* 2013; 8: 66.

16. Herwig R, Kamel A and Shabsigh R. Erectile dysfunction and cavernous veno-occlusive disease. *J Mens Health* 2019; 15: e12–e19.

17. Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. *Postgrad Med J* 2017; 93(1105): 679–685.

18. Montague DK. Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. *Urol Clin* 2011; 38(2): 217–225.

19. Ko OS and Bennett NE Jr. Ambicor two-piece inflatable penile prosthesis: background and contemporary outcomes. *Sex Med Rev* 2017; 6: 319–327.

20. Iyimser U, Ata O and Cavit C. Life quality change after inflatable penile prosthesis implantation. *Aging Male* 2018; 1–7.

21. Loh-Doyle J, Patil MB, Sawkar H, et al. 3-Piece inflatable penile prosthesis placement following radical cystoprostatectomy and urinary diversion: technique and outcomes. *J Sex Med* 2018; 15: 907–913.

22. De Santana Nunes AK, Raposo C, Ana UB, et al. Sildenafil (Viagra®) prevents and restores LPS-induced inflammation in astrocytes. *Neurosci Lett* 2016; 630: 59–65.

23. Islam BN, Sharman SK, Hou Y, et al. Sildenafil suppresses inflammation-driven colorectal cancer in mice. *Cancer Prev Res (Phila)* 2017; 10: 377–388.

24. Laxmi V, Gupta R, Bhattacharya SK, et al. Inhibitory effects of sildenafil and tadalafil on inflammation, oxidative stress and nitrosative stress in animal model of bronchial asthma. *Pharmacol Rep* 2019; 71: 517–521.

25. Fang D, Lin Q, Wang C, et al. Effects of sildenafil on inflammatory injury of the lung in sodium taurocholate-induced severe acute pancreatitis rats. *Int Immunopharmacol* 2020; 80: 106151.

26. Krzastek SC, Smith R. An update on the best approaches to prevent complications in penile prosthesis recipients. *Therap Adv Urol* 2019; 11: 1756287218818076.